BioSpace News Archive

Editas Medicine, Inc., a leading genome editing company, announced three presentations, including one from a research collaboration, at the American Society of Gene and Cell Therapy Annual Meeting being held virtually May 11 – 14, 2021.

Shineco, Inc. announced the Company and Mayah Biological Holdings Limited, a British Virgin Islands Company headquartered in Taiwan Biomedical Park, had signed a Proposal for Purchase of Equity Interest of Mayah Biological Holding Limited, with respect to the potential purchase of at least 51% equity interests in Mayah Biological by the Company.

Pacific Biosciences of California, Inc. announced that its executives will be speaking at the following investor conferences

Durable complete response achieved in 7 of 9 (78%) CD20 sensitive patients who failed Rituxan® therapy in Phase 1 liquid tumor trial Of those patients who responded to the combination therapy of Anktiva™ plus Rituxan, 7 out of 7 (100%) achieved a complete response

Sengenics, the Functional Proteomics Company, announced the appointment of Daniel Tan as Chief Financial Officer and Mark D. Quigley as Vice President of Global Sales and Marketing.

‘4S’ SEASUNBIO SMART SHIELD SYSTEM has been launched in SNU campus as the first mobile COVID-19 diagnostic center in Korea

The Company sees increased technology usage across its installed base and anticipates enrolling to at least 1500 cases by the end of 2021

MIMEDX Group, Inc. (NASDAQ: MDXG) (“MIMEDX” or the “Company”), an industry leader in utilizing amniotic tissue as a platform for regenerative medicine, today urged shareholders to consider several key questions about Prescience Point’s interests, motivations and actions regarding the disruptive proxy fight it is waging to gain undue influence over the MIMEDX Board of Directors

Releviate™ Therapeutics, a bio-pharmaceutical company addressing the needs of patients suffering from neuropathic pain, today welcomes Jennifer Maynard to its scientific advisory board.

FineHeart S.A a preclinical medical device company that has developed the ICOMS FLOWMAKER®, an Implantable Cardiac Output Management System designed to address the unmet need of patients suffering from severe heart failure, today announced the successful, simple, and breakthrough implantation and removal of its device in a 90-day in-vivo trial.